Gammacan International (OTC BB:GCAN), a developer of immunotherapies for cancer and other diseases, today announced that it is considering an additional clinical trial to demonstrate clinical efficacy of hyperimmune intravenous immunoglobulin (IVIg), sourced from a specific population, for treating Melanoma, a common and serious skin cancer. The Company is presently in a Phase II clinical trial utilizing its GCAN - 101 for the treatment of metastatic melanoma, prostate and colon cancers.